Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

November 12, 2026

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Further to our intimation dated November 02, 2026, we wish to inform you that the Board of Directors, at its meeting held today i.e. **November 12, 2026**, has, inter-alia approved the Un-audited standalone and consolidated financial results **(Annexure 1)** along with the Limited Review Report as per Indian Accounting Standards for the quarter and half year ended September 30, 2026. We enclose Press Release issued by the Company **(Annexure 2)**, an investor presentation **(Annexure 3)** and Limited review report **(Annexure 4)** in this regard.

The meeting commenced at 11.15 A.M and concluded at 1.00 P.M.

Kindly take the same on your records.

Sincerely Yours
For Caplin Point Laboratories Limited

VENKATRAM GANAPATHISUBRAMANIAN
Digitally signed by VENKATRAM GANAPATHISUBRAMANIAN
Date: 2026.11.12 13:03:18 +05'30'

Venkatram G
General Counsel & Company Secretary
Membership No. A23989
Encl: A/a

ANNEXURE - 1

CAPLIN POINT LABORATORIES LIMITED

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

	Particulars	Quarter Ended			Half year Ended		Year Ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
		₹ In Crores					
	Income						
I	Revenue from operations	241.88	202.95	175.18	444.83	357.75	738.33
II	Other income	51.04	62.79	59.22	113.83	91.25	195.37
III	**Total Income (I+II)**	**292.92**	**265.74**	**234.40**	**558.66**	**449.00**	**933.70**
IV	**Expenses**						
	a. Cost of materials consumed	48.06	42.12	34.92	90.18	73.54	158.82
	b. Purchase of traded goods	27.59	27.42	21.21	55.01	34.39	82.51
	c. Changes in inventories of finished goods, stock in trade and work in progress	(5.51)	(11.38)	2.05	(16.89)	8.32	(12.37)
	d. Employee benefits expense	13.55	13.73	11.54	27.28	21.17	47.72
	e. Finance costs	0.06	0.05	0.05	0.11	0.09	0.20
	f. Depreciation & Amortisation Expense	7.07	6.56	6.02	13.63	12.16	25.43
	g. Other Expenses	35.05	36.65	29.61	71.70	57.87	123.87
	Total Expenses	**125.87**	**115.15**	**105.40**	**241.02**	**207.54**	**426.18**
V	**Profit before exceptional items and Tax (III-IV)**	**167.05**	**150.59**	**129.00**	317.64	**241.46**	**507.52**
VI	Exceptional items	-	-	-	-	-	-
VII	**Profit Before Tax (V-VI)**	**167.05**	**150.59**	**129.00**	**317.64**	**241.46**	**507.52**
VIII	**Tax Expenses**						
	(1) Current Tax	36.79	28.76	26.77	65.55	53.68	109.49
	(2) Deferred Tax	(0.25)	1.45	(0.36)	1.20	(0.70)	1.45
	Total Tax Expenses	**36.54**	**30.21**	**26.41**	**66.75**	**52.98**	**110.94**
IX	**Net Profit for the period (VII-VIII)**	**130.51**	**120.38**	**102.59**	**250.89**	**188.48**	**396.58**
X	**Other Comprehensive Income/ (Loss) - Net of Tax**						
	A. Items that will not be re-classified to profit or loss						
	i) Remeasurements of Defined Benefit Plan	0.51	-	0.67	0.51	0.67	(0.09)
	ii) Income tax relating to these items	(0.13)	-	(0.17)	(0.13)	(0.17)	0.02
XI	**Total Comprehensive Income For The Period (IX+X)**	**130.89**	**120.38**	**103.09**	251.27	**188.98**	**396.51**
XII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20
XIII	Other equity						2,035.30
XIV	**Earnings Per Share (EPS) of Face value Rs 2/- per Equity share***						
	(a) Basic (in Rupees)	**17.17**	**15.84**	**13.50**	**33.01**	**24.80**	**52.17**
	(b) Diluted (in Rupees)	**17.12**	**15.79**	**13.45**	**32.91**	**24.71**	**52.02**
		***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Annualised)**

See Accompanying notes to Financial Results

BRAHMAYYA & CO. For Identification Only CHARTERED ACCOUNTANTS

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED

STANDALONE BALANCE SHEET AS AT SEPTEMBER 30, 2026

(All amounts mentioned are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited) As at September 30, 2026	(Audited) As at March 31, 2026
ASSETS		
(1) Non-Current Assets		
(a) Property, plant and equipment	203.40	219.68
(b) Capital work-in-progress	14.77	9.39
(c) Intangible assets	0.92	1.24
(d) Right of use assets	1.93	2.00
(e) Financial assets		
(i) Investments	888.28	704.73
(ii) Loans	267.54	267.54
(iii) Other financial assets	35.41	18.04
(f) Income tax assets (Net)	-	2.82
(g) Other non-current assets	0.46	10.42
Total- Non-current assets	**1,412.71**	**1,235.86**
(2) Current Assets		
(a) Inventories	103.47	85.66
(b) Financial assets		
(i) Investments	358.20	342.51
(ii) Trade receivables	320.48	265.96
(iii) Cash and cash equivalents	32.83	44.09
(iv) Bank balances other than (iii) above	121.94	161.99
(v) Other financial assets	20.26	39.42
(c) Other current assets	38.94	36.25
Total- Current assets	**996.12**	**975.88**
Total	**2,408.83**	**2,211.74**
EQUITY AND LIABILITIES		
(1)Equity		
(a) Equity share capital	15.20	15.20
(b) Other equity	2,226.09	2,035.30
Total-Equity	**2,241.29**	**2,050.50**
(2) Liabilities		
(A) Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease liabilities	0.98	1.34
(b) Deferred tax liabilities (Net)	12.00	10.67
(c) Income tax Liability (Net)	2.84	-
(d) Other non current liabilities	2.58	2.85
(e) Provisions	2.63	2.21
Total-Non current liabilities	**21.03**	**17.07**
(3) Current Liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) total outstanding dues of micro and small enterprises	4.44	4.46
(b) total outstanding dues other than micro and small enterprises	77.12	88.56
(ii) Lease liabilities	1.18	0.85
(iii) Other financial liabilities	23.57	19.77
(b) Provisions	8.07	9.10
(c) Other current liabilities	32.13	21.43
Total-Current liabilities	**146.51**	**144.17**
Total	**2,408.83**	**2,211.74**

BRAHMAYYA & CO. For Identification Only CHARTERED ACCOUNTANTS

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited) For the half year ended September 30,2026	(Unaudited) For the half year ended September 30, 2025
A. Cash Flow from Operating Activities		
Profit before tax	**317.64**	**241.46**
Adjustments for:		
Depreciation and amortisation expense	13.63	12.16
Finance costs	0.11	0.09
Government grant	(0.33)	(0.29)
(Profit)/Loss on sale/disposal of property, plant and equipment	(0.14)	2.60
Employee stock option scheme expense	0.37	(1.82)
Net unrealised foreign exchange fluctuation loss (gain)	7.34	(6.15)
Fair value loss/(gain) on financial instruments through profit or loss	(1.24)	(2.29)
Realised gain on financial assets	(2.19)	(2.24)
Dividend income	(44.09)	(31.75)
Interest income	(47.92)	(41.46)
Operating Profit before working capital changes	**243.18**	**170.31**
Adjustments for :		
(Increase) / Decrease in inventories	(17.81)	6.23
(Increase) / Decrease in trade receivables	(62.11)	(68.56)
(Increase) / Decrease in other assets	(2.69)	(8.10)
(Increase) / Decrease in other financial assets	0.66	0.23
Increase / (Decrease) in trade payables, other liabilities & provisions	2.59	29.16
Cash generated from operations	**163.82**	**129.27**
Income tax Paid	(59.89)	(52.12)
Net Cash inflow / (outflow) from operating activities	**103.93**	**77.15**
B. Cash Flow from Investing Activities		
Sale / (Purchase) of investments	(134.55)	(90.23)
Investment in bank deposits & inter corporate deposits	(0.37)	(5.85)
Investment in subsidiaries	(64.00)	-
Loan repayment by/(given to) subsidiary (net)	-	(11.40)
(Increase)/ decrease in other bank balances	40.12	0.04
Sale/ (purchase) of property, plant and equipment (including CWIP)	8.58	(28.64)
Interest received	49.42	40.40
Dividend received	44.09	31.75
Realised gain on financial assets	2.19	2.24
Net Cash inflow/(outflow) from investing activities	**(54.52)**	**(61.69)**
C. Cash Flow from Financing Activities		
Interest paid (Including interest on Lease liability)	(0.11)	(0.09)
Dividend paid	(60.81)	(45.61)
Net Cash inflow / (outflow) from financing activities	**(60.92)**	**(45.70)**
Net increase / (decrease) in cash and cash equivalents during the period D=(A+B+C)	**(11.51)**	**(30.24)**
Cash and cash equivalents as at the beginning of the period (E)	**44.09**	**99.64**
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	0.17
Cash and cash equivalents as at the end of the period (G=D+E+F)	**32.83**	**69.57**
Less: Bank Balance in Unspent CSR Account (H)	0.01	0.01
Net cash and cash equivalents as at the end of the period (I=G-H)	**32.82**	**69.56**





CAPLIN POINT LABORATORIES LIMITED

Standalone Notes:

1) The above Standalone financial Results for the quarter and half year ended September 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2026 and reviewed by the Statutory Auditors.

2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company.

4) Other Income and Profit Before Tax includes:

	Quarter ended			Half Year Ended		Year Ended
Particulars	**30.09.2026**	**30.06.2026**	**30.09.2025**	**30.09.2026**	**30.09.2025**	**31.03.2026**
Dividend from wholly owned subsidiary- Caplin Point Far East Limited	15.19	28.90	23.63	44.09	31.75	62.30

5) The Shareholders, at their General Meeting held on September 25, 2026 approved a final dividend of ₹ 4.00/- (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on October 7, 2026.
The total dividend for the financial year 2025-26 including the Interim and Final dividend is ₹ 8.00/- (Rs. Eight Only) per equity share (400%) of the face value of ₹ 2 each.

6) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.

BRAHMAYYA & CO. CHARTERED ACCOUNTANTS For Identification Only

For and on behalf of the Board

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096

Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: November 12, 2026

CAPLIN POINT LABORATORIES LIMITED

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

	Particulars	Quarter Ended			Half year Ended		Year Ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
		₹ in Crores					
	Income						
I	Revenue from operations	629.84	610.36	534.04	1,240.20	1,044.26	2,187.19
II	Other income	33.29	33.55	30.37	66.84	53.51	115.54
III	**Total Income (I+II)**	**663.13**	**643.91**	**564.41**	**1,307.04**	**1,097.77**	**2,302.73**
IV	**Expenses**						
	a. Cost of materials consumed	106.15	107.06	92.34	213.21	165.85	357.20
	b. Purchase of traded goods	150.31	196.36	121.68	346.67	235.18	572.20
	c. Changes in inventories of finished goods, stock in trade and work in progress	(17.79)	(58.22)	(3.72)	(76.01)	4.51	(63.72)
	d. Employee benefits expense	57.59	57.03	48.03	114.62	92.08	199.15
	e. Finance costs	0.22	0.18	0.16	0.40	0.34	0.87
	f. Depreciation & Amortisation Expense	23.49	21.62	18.40	45.11	34.69	72.77
	g. Other Expenses	110.36	94.65	86.54	205.01	179.71	361.51
	Total Expenses	**430.33**	**418.68**	**363.43**	**849.01**	**712.36**	**1,499.98**
V	**Profit before share of profit in Associate, Exceptional Items and tax (III-IV)**	**232.80**	**225.23**	**200.98**	**458.03**	**385.41**	**802.75**
VI	Share of Profit/(Loss) in Associate	0.03	(0.01)	0.02	0.02	0.05	0.04
VII	Exceptional items	-	-	-	-	-	-
VIII	**Profit Before Tax (V+VI+VII)**	**232.83**	**225.22**	**201.00**	**458.05**	**385.46**	**802.79**
IX	**Tax Expenses**						
	(1) Current Tax	54.78	46.18	36.53	100.96	69.63	146.29
	(2) Deferred Tax	(4.30)	(0.05)	4.24	(4.35)	4.84	6.77
	Total Tax Expenses	**50.48**	**46.13**	**40.77**	**96.61**	**74.47**	**153.06**
X	**Net Profit for the period (VIII - IX)**	**182.35**	**179.09**	**160.23**	**361.44**	**310.99**	**649.73**
XI	**Other Comprehensive Income - Net of Tax**						
	A. Items that will not be re-classified to profit or loss						
	i) Remeasurements of Defined Benefit Plan	1.06	-	1.34	1.06	1.34	0.29
	ii) Income tax relating to these items	(0.27)	-	(0.34)	(0.27)	(0.34)	(0.07)
	B. Items that will be re-classified to profit or loss						
	i) Exchange difference in translating the financial statements of foreign operations	24.36	(1.86)	46.54	22.50	46.90	141.42
XII	**Total Comprehensive Income For The Period (X + XI)**	**207.50**	**177.23**	**207.77**	**384.73**	**358.89**	**791.37**
XIII	**Profit attributable to:**						
	Owners of the Company	178.10	176.91	154.45	355.01	307.25	641.24
	Non- controlling interests	4.25	2.18	5.78	6.43	3.74	8.49
		182.35	**179.09**	**160.23**	**361.44**	**310.99**	**649.73**
XIV	**Total Comprehensive Income For The Period attributable to**						
	Owners of the Company	203.25	175.05	201.99	378.30	355.15	782.88
	Non- controlling interests	4.25	2.18	5.78	6.43	3.74	8.49
		207.50	**177.23**	**207.77**	**384.73**	**358.89**	**791.37**
XV	Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20
XVI	Other equity excluding Non-controlling interest						3,571.22
XVII	**Earnings Per Share (EPS) of Face value Rs 2/- per Equity share***						
	(a) Basic (in Rupees)	**23.44**	**23.27**	**20.32**	**46.71**	**40.42**	**84.36**
	(b) Diluted (in Rupees)	**23.37**	**23.21**	**20.25**	**46.58**	**40.28**	**84.11**
		***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Annualised)**

See Accompanying notes to Financial Results

BRAHMAYYA & CO. CHARTERED ACCOUNTANTS For Identification Only

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED
CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30,2026
(All amounts mentioned are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited) As at September 30, 2026	(Audited) As at March 31, 2026
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	653.12	547.49
(b) Capital work-in-progress	215.45	208.62
(c) Intangible assets	28.38	28.87
(d) Right of use assets	3.43	3.65
(e) Intangible assets under development	24.96	24.96
(f) Financial assets		
(i) Investments	593.43	473.31
(ii) Other financial assets	45.92	28.40
(g) Income tax assets (net)	-	11.30
(h) Deferred tax assets	13.35	7.97
(i) Other non-current assets	100.05	125.25
Total non-current assets	**1,678.09**	**1,459.82**
(2) Current Assets		
(a) Inventories	544.03	428.86
(b) Financial assets		
(i) Investments	372.42	385.71
(ii) Trade receivables	889.39	825.81
(iii) Cash and cash equivalents	86.62	94.18
(iv) Other bank balances	489.26	526.86
(v) Other financial assets	54.45	74.17
(c) Other current assets	260.67	250.07
Total current assets	**2,696.84**	**2,585.66**
Total assets	**4,374.93**	**4,045.48**
EQUITY AND LIABILITIES		
(1) Equity		
Equity share capital	15.20	15.20
Instruments entirely equity in nature	74.58	74.58
Other equity	3,812.67	3,496.64
Equity attributable to shareholders of the company	**3,902.45**	**3,586.42**
Non-controlling interest	50.81	44.38
Total equity	**3,953.26**	**3,630.80**
(2) Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	1.88	2.06
(b) Deferred tax liabilities	13.36	12.60
(c) Provisions	1.44	1.00
(d) Income tax Liabilities (Net)	9.21	-
(e) Other non current liabilities	29.72	13.06
Total non-current liabilities	**55.61**	**28.72**
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	0.78	0.57
(ii) Trade payables		
(a) Total outstanding dues of micro and small enterprises	9.97	9.26
(b) Total outstanding dues other than (ii) (a) above	264.32	286.77
(iii) Lease liabilities	1.96	1.98
(iv) Other financial liabilities	50.17	50.76
(b) Provisions	21.56	20.02
(c) Other current liabilities	17.30	16.60
Total current liabilities	**366.06**	**385.96**
Total equity and liabilities	**4,374.93**	**4,045.48**

BRAHMAYYA & CO. CHARTERED ACCOUNTANTS For Identification Only
CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2026
(All amounts are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited) For the half year ended September 30, 2026	(Unaudited) For the half year ended September 30, 2025
A. Cash Flow from Operating Activities		
Profit before tax	**458.05**	**385.46**
Adjustments for:		
Depreciation and amortisation expense	45.11	34.69
Finance costs	0.40	0.34
Government grant	(1.99)	(1.18)
(Profit)/Loss on sale/disposal of property, plant and equipment	(0.20)	2.72
Employee stock option scheme expense	0.37	(0.68)
Net unrealised foreign exchange fluctuation loss (gain)	7.34	(6.15)
Fair value (gain)/loss on financial instruments through profit or loss	(1.26)	(2.68)
Realised gain on financial assets	(3.05)	(2.69)
Share of (profit)/loss in associate	(0.02)	(0.05)
Interest income	(45.30)	(36.73)
Operating Profit before Working Capital changes	**459.45**	**373.05**
Adjustments for :		
(Increase) / decrease in inventories	(115.17)	9.94
(Increase) / decrease in trade receivables	(71.17)	(55.24)
(Increase) / decrease in other financial assets	0.21	(7.50)
(Increase) / decrease in other assets	(10.60)	(20.65)
Increase / (decrease) in trade payables, other liabilities & provisions	0.48	(28.09)
Impact of foreign currency translation	22.50	46.90
CASH GENERATED FROM OPERATIONS	**285.70**	**318.41**
Income tax paid (net)	(80.45)	(64.67)
Net cash inflow / (outflow) from operating activities (A)	**205.25**	**253.74**
B. Cash Flow from Investing Activities		
Payment for acquisition of subsidiaries (net)	-	(0.05)
Sale / (purchase) of investments	(105.55)	(43.27)
Investment / (redemption) in bank deposits & debentures	(0.38)	(50.85)
(Increase) / decrease in other bank balances	37.60	(146.86)
Sale / (purchase) of property, plant and equipment (including cwip)	(134.46)	(93.88)
Interest received	47.67	33.13
Realised gain on financial assets	3.05	2.69
Net cash inflow / (outflow) from investing activities (B)	**(152.07)**	**(299.09)**
C. Cash Flow from Financing Activities		
Increase / (decrease) in long and short term borrowings	0.22	(0.06)
Interest paid (including interest on lease liability)	(0.40)	(0.34)
Dividend paid	(60.81)	(45.61)
Net Cash inflow / (outflow) from financing activities (C)	**(60.99)**	**(46.01)**
Net increase / (decrease) in cash and cash equivalents during the period (D=A+B+C)	**(7.81)**	**(91.36)**
Cash and cash equivalents as at the beginning of the period (E)	**94.18**	**199.45**
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	0.17
Cash and cash equivalents as at the end of the period (G=D+E+F)	**86.62**	**108.26**
Less: Bank balance in unspent CSR account (H)	0.01	0.01
Net cash and cash equivalents as at the end of the period (I=G-H)	**86.61**	**108.25**





CAPLIN POINT LABORATORIES LIMITED

Segment Information (Consolidated)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	₹ in Crores					
1) Segment revenue (Total Revenue)						
Rest of the World	500.12	476.07	427.08	976.19	830.61	1,733.79
USA	129.72	134.29	106.96	264.01	213.65	453.40
Unallocated	33.29	33.55	30.37	66.84	53.51	115.54
Total	**663.13**	**643.91**	**564.41**	**1,307.04**	**1,097.77**	**2,302.73**
2) Segment results (PBT)						
Rest of the World	183.22	158.40	156.10	341.62	307.56	631.20
USA	16.32	33.27	14.53	49.59	24.39	56.05
Unallocated	33.29	33.55	30.37	66.84	53.51	115.54
Total	**232.83**	**225.22**	**201.00**	**458.05**	**385.46**	**802.79**
3) Segment Assets						
Rest of the World	2,102.09	2,021.21	1,588.42	2,102.09	1,588.42	1,918.28
USA	739.00	672.75	581.33	739.00	581.33	656.00
Unallocated	1,533.84	1,502.39	1,334.17	1,533.84	1,334.17	1,471.20
Total	**4,374.93**	**4,196.35**	**3,503.92**	**4,374.93**	**3,503.92**	**4,045.48**
4) Segment Liabilities						
Rest of the World	320.24	350.80	251.39	320.24	251.39	332.52
USA	101.43	69.79	53.54	101.43	53.54	82.16
Unallocated	-	-	-	-	-	-
Total	**421.67**	**420.59**	**304.93**	**421.67**	**304.93**	**414.68**





CAPLIN POINT LABORATORIES LIMITED

Consolidated Notes:

1) The above Consolidated Financial Results for the quarter and half year ended September 30, 2026, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on November 12, 2026, and reviewed by the Statutory Auditors.

2) The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results.

4) The Shareholders, at their General Meeting held on September 25, 2026 approved a final dividend of ₹ 4.00/- (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on October 7, 2026.
The total dividend for the financial year 2025-26 including the Interim and Final dividend is ₹ 8.00/- (Rs. Eight Only) per equity share (400%) of the face value of ₹ 2 each.

5) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

BRAHMAYYA & CO. For Identification Only CHARTERED ACCOUNTANTS

For and on behalf of the Board

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: November 12, 2026

H1 FY27 Total revenue crosses ₹1,300 Crores; an increase of 19.1% YoY

H1 FY27 EBITDA crosses ₹500 Crores; an increase of 19.8% YoY

H1 FY27 PAT at ₹361 Crores; an increase of 16.2% YoY

US Market H1 FY27 Total Revenue ₹271 Crores; an increase of 22.8% YoY, CSU achieves FY26 sales in H1 of FY27

Free Cash Reserves at ₹1,534 Crores; Liquid Assets at ₹2,967 Crores.

Chennai, 12th November 2026: Caplin Point Laboratories Ltd. ("Caplin Point" or the "Company") (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter and half year ended September 30, 2026.

Consolidated Financial Performance for Q2 FY27 & H1 FY27:

₹ in Crores

Particulars	Q2 FY27	Q2 FY26	YoY (%)	Q1 FY 27	QoQ (%)	*H1 FY27*	*H1 FY26*	YoY (%)
Revenue from Operations	629.8	534.0	*17.9%*	610.4	*3.2%*	1,240.2	1,044.3	*18.8%*
Total Revenue	663.1	564.4	*17.5%*	643.9	*3.0%*	1,307.0	1,097.8	*19.1%*
Gross Profit	391.2	323.7	*20.8%*	365.2	*7.1%*	756.3	638.7	*18.4%*
Gross Margin %	*62.1%*	*60.6%*		*59.8%*		*61.0%*	*61.2%*	
EBITDA	256.5	219.5	*16.8%*	247.0	*3.8%*	503.5	420.4	*19.8%*
EBITDA Margin %	*38.7%*	*38.9%*		*38.4%*		*38.5%*	*38.3%*	
Profit Before Tax	232.8	201.0	*15.8%*	225.2	*3.4%*	458.1	385.5	*18.8%*
PBT Margin %	*35.1%*	*35.6%*		*35.0%*		*35.0%*	*35.1%*	
Profit after Tax	182.4	160.2	*13.8%*	179.1	*1.8%*	361.4	311.0	*16.2%*
PAT Margin	*27.5%*	*28.4%*		*27.8%*		*27.7%*	*28.3%*	

Other Consolidated Financial Highlights for Q2 FY27 & H1FY27:

- Gross Margin for Q2 FY27 is 62.1% vs 60.6% in Q2 FY26 and H1 FY27 is 61.0% vs 61.2% in H1 FY26.
- EBITDA Margin for H1 FY27 is at 38.5% vs 38.3% in H1 FY26 and Q2 FY27 is 38.7% vs 38.9% in Q2 FY26.
- Basic EPS increased by 15.5% to ₹46.71 in H1 FY27 compared to ₹40.42 in H1 FY26.
- Cash Flow from Operations in H1 FY27 is ₹205 Crores vs ₹254 Crores in H1 FY26.
- Free Cash Flow is ₹70 Crores (after Capex investment of ₹135 Crores) in H1 FY27 as compared to ₹160 Crores (after capex investment of ₹94 Crores) in H1 FY26.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for H1 FY27 is in the range of 79% and 21% respectively.
- CSL's Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for H1FY27 in the range of 82% and 18% respectively.
- As of 30th September 2026, Inventories are at ₹544 Crores - 45% Stock at the warehouses, close to the customer; In Transit 18%; 37% in India. Receivables stood at 129 days.
- As of 30th September 2026, Free Cash reserves are at ₹1,534 Crores and Total Liquid Assets at ₹2,967 Crores.

Business Highlights for Q2FY27:

Emerging Markets:

- Caplin continues steady and consistent growth in Latin America across all geographies and segments.
- Central America update – Company has won tenders to the tune of $5.3 million to be supplied over the next 3 Quarters. Around 70% of that is Oncology products, which move more through Tenders.
- Chile Update – Caplin continues to show strong growth in Chile in both Private and Tender market sales. Company has won new tenders to the tune of $5 million to be supplied over the next 18 months. Company has 6 products accepted by the 3 largest Pharmacy Chains in the country, for annual supplies.
- Mexico Update – Company has started commercial sales of Oncology products in Mexico recently. Company has received 4 new product approvals this Quarter, with a further 13 products under active review with COFEPRIS. The company is working on a pipeline of 110+ products to be filed in the next 18 months, in addition to the 33 approvals received. The company is in the midst of due diligence for a potential acquisition of a Distribution company in Mexico.
- Oncology Unit update – Caplin One Labs oncology facility in Kakkalur, completes Exhibit Batches for 4 Injectables and OSD products. Additionally, submission batches for 16 products are planned in the next 12 months, for LatAm, US and EU markets. The company is in the midst of due diligence for around 12+ Oncology ANDAs that are approved or filed for approval, for potential acquisition.
- API unit at Vizag for General Category products: Commercial license received for the unit, with first commercial product supplied to parent company from this site. First DMFs expected to be filed from this unit within FY27.
- Caplin's Oncology API unit in Thervoy, TN, will be completed by CY27, with first DMFs filed from this plant in the following year.
- Company's new project involving OSD and Dermatology divisions in Pondy continues progress at full swing. The facility is aimed at expansion of capacities by over 2X of the existing capacities. This facility is aimed at meeting growing capacity demand in existing markets and also entry into Regulated markets for these dosages.
- Amaris Clinical update – Multiple OSD and Softgel products pivotal BE studies completed recently, from internal R&D pipeline. To cater to additional demands from internal pipeline products, Company starts expansion activities at Amaris Clinical to increase capacity up to 120 Beds. Project is expected to be completed by end of FY27.

US & Regulated Markets:

- Caplin Steriles Limited (CSL) continues steady growth across all parameters. Split between B2B and B2C revenues currently at 60/40, as the company's front end gains momentum.
- CSL has filed 120+ products (of which 75 are approved) in multiple Non-US markets, such as Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE etc. Plans in place to file 60+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27 / FY28.
- Company has launched 40 products in the US till date, with plans to launch 10 more products in FY28.
- CSL completed Exhibit Batches for 2 Pre-Filled Syringe products from this site. Company has another 12 Pre-Filled Syringe products under active development, which will be filed in FY28.

- Company has completed movement from physical Logbooks to electronic Logbooks and move underway towards electronic Batch Manufacturing and Packing Records within the next few months. Company has already achieved total automation in Quality Control and Microbiology areas at the site.
- To cater to the growing capacity needs at CSL, company's COL-II facility construction will be completed by Aug '27 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction.
- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**
  - CSU continues remarkable progress in the US, with H1 sales outpacing FY26 sales in the US.
  - Within its second full year of operations, over 5600 unique customers purchase CSU's products, an increase of 20% over FY26. CSU has added multiple direct sales contracts with large and small IDNs, in addition to the major Wholesalers in the US.
  - Average sales per day has nearly doubled from $32,936 in FY26 to $61,330 per day, as on date. Company expects to double its revenue and profit over FY26.

Commenting on the H1-FY27 performance, Mr. C.C. Paarthipan, Chairman said:


"H1 FY27 has been another half of disciplined, broad-based growth for Caplin Point. Total revenue crossed ₹1,300 Crores and EBITDA crossed ₹500 Crores, both up close to 20% year-on-year, and our margins have held firm. Our Latin American business keeps getting stronger: we won new tenders in Central America and Chile, started oncology sales in Mexico, and have a strong R&D pipeline that positions us well in one of our high target growth markets. In the US, Caplin Steriles USA has surpassed its full FY26 sales in just the first six months of its second full year, which shows how quickly our own-label business is winning customers. We are reinvesting what we earn into new capacity and capabilities, including oncology, APIs, the COL-II facility, pre-filled syringes and digitalisation. With free cash reserves of ₹1,534 Crores, we have the balance sheet to fund this expansion from a position of strength. I thank our employees, partners and shareholders for their continued trust as we build a more integrated and more global Caplin Point."

Strategic Growth Initiatives

Project Summary					
Facility	**Location**	**Product**	**Target Market**	**Status**	**Timeline**
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity Completed	CY27
OSD Facility	Puducherry	OSD and Dermatology	New Markets such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmic	Regulated Markets	Civil & Structural activity ongoing at full swing	Q2 FY28

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the investments are expected to be completed over the next 2 years, and the respective projects are expected to be fully commercialised within 1 year from the completion of the investments. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.

Tamil Nadu, India



Andhra Pradesh, India



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes "Asia's 200 Best Under a Billion" list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

For further information, please contact:

G Venkatram,
General Counsel & Company Secretary
Caplin Point Laboratories Limited

+91 44 2496 8000
investor@caplinpoint.net

Soham Arora / Simran Malhotra
Churchgate Partners

+91 73032 11037
caplinpoint@churchgatepartners.com

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor it's directors, or any of it's subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.

Caplin Point
Laboratories Limited

ANNEXURE - 3



EARNINGS PRESENTATION Q2 & H1 FY27

Rated #1 in India for "*Most Consistent Profitable Growth across the last 10 years*"

*Second Largest wealth creator for the decade ending 2020**

November 2026 | www.caplinpoint.net

#Value Research magazine – Wealth Insight June 2022 issue
*The Economic Times

Evolution Over the Decades

Caplin Point Laboratories Limited

1990 — Incorporation

1994 — Listed on Stock Exchange

2001 — Entered Angola with unique Stock & Sale model

2005 — Started outsourcing from China

2006 — Entered the Caribbean and Latin America

2014 — Work on Regulated Markets Injectable unit starts

2017 — Liquid injectable facility gets EU & USFDA Approval

2018 — Started first commercial shipments to US

2019 — Fidelity investment into Caplin Steriles

2021 — Rs. 600 Cr. Expansion, CRO wing Amaris Clinical gets USFDA approval

2022 — Acquires API plant in Vizag, as part of backward integration move. Amaris Clinical gets ISP Chile approval

2023 — Incorporates Caplin Steriles USA Inc for launching own label in US

2024 — Oncology facility started production at SIDCO Kakkalur, Chennai

2025 — CSU commencement of operations

2026 — Acquires 10 ANDAs; receives multiple USFDA approvals. Chile subsidiary starts commercial operation Receives INVIMA GMP compliance confirmation

Contract manufacturer

- Market-led Company
- Plain vanilla generic products
- Introducing products that plugged marketplace gaps
- Negative-working capital business
- 2 main geographies 10 countries (Latin America & Francophone Africa)

Becoming a responsible pharma company

- Technology and research-led marketing Company
- Mix of generics, branded generics and speciality molecules and Injectables
- Launch speciality niche products that Create new markets in varied therapy segments
- Selective use of Credit strategy to increase market share and remain cash surplus
- Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly


Diversified Product Portfolio

- 5,000+ Products registered and 650+ Pharmaceutical formulations
- 36 Therapeutic Segments
- Product mix covers over 65% of WHO essential drug list
- Latest focus towards complex spaces
- Accounts for larger shelf share across pharmacies on account of a widening product basket


Q2 FY27 Income Statement

Caplin Point Laboratories Limited


Revenue from Operations




Gross Profit




EBITDA




EBIT



PAT



Earnings Per Share




(All figures in Rs. Crores except EPS in Rs.)


Q2 FY27 Profit Margins

Caplin Point Laboratories Limited


Gross Profit Margins (%)




EBITDA Margins (%)



EBIT Margins (%)




PAT Margins (%)




H1 FY27 Income Statement

Caplin Point Laboratories Limited


Revenue from Operations




Gross Profit




EBITDA




EBIT



PAT



Profit Margins




(All figures in Rs. Crores)


H1 FY27 Cash and Cash Equivalents and other Key Metrics

Caplin Point Laboratories Limited

Cash and Cash Equivalents (Rs. Cr)



Capital Investment Lifecycle (Rs. Cr)




Cash Flow from Operation: ₹ **205** Cr


Free Cashflow: ₹ **70** Cr

Receivables: **129** Days

ROE (%)



ROCE (%)



Leadership Team

Caplin Point Laboratories Limited

Chairman Perspectives



Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

"H1 FY27 has been another half of disciplined, broad-based growth for Caplin Point. Total revenue crossed ₹1,300 Crores and EBITDA crossed ₹500 Crores, both up close to 20% year-on-year, and our margins have held firm. Our Latin American business keeps getting stronger: we won new tenders in Central America and Chile, started oncology sales in Mexico, and have a strong R&D pipeline that positions us well in one of our high target growth markets. In the US, Caplin Steriles USA has surpassed its full FY26 sales in just the first six months of its second full year, which shows how quickly our own-label business is winning customers. We are reinvesting what we earn into new capacity and capabilities, including oncology, APIs, the COL-II facility, pre-filled syringes and digitalisation. With free cash reserves of ₹1,534 Crores, we have the balance sheet to fund this expansion from a position of strength. I thank our employees, partners and shareholders for their continued trust as we build a more integrated and more global Caplin Point."

Management Team

Dr. Sridhar Ganesan

- Managing Director



Mr. D Muralidharan

- Whole Time Director and Chief Financial Officer



Q2 FY27 Highlights (Emerging Markets)

Caplin Point Laboratories Limited

01

Caplin continues steady and consistent growth in Latin America across all geographies and segments

02

Company has won tenders to the tune of $5.3 million to be supplied over the next 3 Quarters. Around 70% of that is Oncology products, which move more through Tenders

03

Chile Update – Caplin continues to show strong growth in Chile in both Private and Tender market sales. Company has won new tenders to the tune of $5 million to be supplied over the next 18 months. Company has 6 products accepted by the 3 largest Pharmacy Chains in the country

04

Mexico Update – Commenced commercial sales of Oncology products in Mexico and received 4 approvals, with 13 products under COFEPRIS review, 110+ planned for filing in next 18 months and 33 existing approvals. Due diligence is underway for a potential Mexican distribution company acquisition

05

Oncology Unit update – Completed Exhibit Batches for 4 Injectables and OSD products. Submission batches for 16 products are planned in the next 12 months. The company is in the midst of due diligence for around 12+ Oncology ANDAs that are approved or filed for approval, for potential acquisitions

Emerging Markets Business Highlights

06

API unit at Vizag for General Category products: Commercial license received for the unit, with first commercial product supplied to parent company from this site. First DMFs expected to be filed from this unit within FY27

07

Caplin's Oncology API unit in Thervoy, TN, will be completed by CY27, with first DMFs filed from this plant in the following year

08

Company's new project involving OSD and Dermatology divisions in Pondy continues progress at full swing. The facility is aimed at expansion of capacities by over 2X of the existing capacities

09

The OSD and Dermatology divisions in Pondy facility is aimed at meeting growing capacity demand in existing markets and also entry into Regulated markets for these dosages

10

Amaris Clinicals update – Multiple OSD and Softgel products pivotal BE studies completed recently pipeline. To cater to additional demands from internal pipeline products, Company starts expansion activities at Amaris Clinical to increase capacity up to 120 Beds. Project is expected to be completed by end of FY27

Q2 FY27 Highlights (US and Regulated markets)

Caplin Point Laboratories Limited

01

Caplin Steriles Limited (CSL) continues steady growth across all parameters. Split between B2B and B2C revenues currently at 60/40, as the company's front end gains momentum

02

CSL has filed 120+ products (of which 75 are approved) in multiple Non-US markets, such as Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE etc

03

Plans in place to file 60+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27 / FY28

04

Company has launched 40 products in the US till date, with plans to launch 10 more products in FY28

05

CSL completed Exhibit Batches for 2 Pre-Filled Syringe products from this site. Company has another 12 Pre-Filled Syringe products under active development, which will be filed in FY28

US and Regulated Markets Business Highlights

06

Company has completed movement from physical Logbooks to electronic Logbooks, and move underway towards electronic Batch Manufacturing and Packing Records within the next few months. Company has already achieved total automation in Quality Control and Microbiology areas at the site

07

To cater to the growing capacity needs at CSL, company's COL-II facility construction will be completed by Aug '27 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction

08

CSU continues remarkable progress in the US, with H1 sales nearly outpacing FY26 sales in the US

09

Within its second full year of operations, over 5600 unique customers purchase CSU's products, an increase of 20% over FY26. CSU has added multiple direct sales contracts with large and small IDNs, in addition to the major Wholesalers in the US


10

Average sales per day has nearly doubled from $32,936 in FY26 to $61,330 per day, as on date. Company expects to double its revenue and profit over FY26


Research & Development Capabilities

Caplin Point Laboratories Limited

1. Caplin has 5 dedicated R&D setups (3 – DSIR approved).
2. Continuous capex investment of over Rs. 870 Cr over last 5 years towards enhanced manufacturing and R&D capabilities, from internal accruals.
3. Total R&D Spends (Capex + Opex) is 15.5% of FY26 PAT.
4. Caplin ranks amongst the top companies in India, for R&D spend as a percentage of Revenue on average in the past 5 years.*
5. Completed R&D for 90+ APIs to be used for backward integration in US and Emerging markets. First DMF filing targeted by end of FY2027.



399
Strength of R&D Team





Research and Development along with conscious conversion of certain fast-selling generics into Branded Generics for better profitability


*Source – CNBC-TV18, Dec 31st 2020

Including Partners and Bought Out


Revenue Break up and Manufacturing Strategy

Caplin Point Laboratories Limited


FY26 Operating Revenue



Revenue by Business Segment (Emerging Markets)




Revenue by Channel (Emerging Markets)




Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,303 Cr in FY26

Manufacturing & Outsourcing



Exports



Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Generics and Branded Generics Product Mix

Caplin Point Laboratories Limited



Non-Steroidal Antiinflammatory Drugs-NSAIDS



Antihelminthics/ Dewormer



Analgesic



Antibiotic and Antifungal



Antihypertensive drug



Electrolytes

Caplin Point Structure

Caplin Point Laboratories Limited

Caplin Point Laboratories Ltd (BSE: 524742| NSE: CAPLIPOINT)

Manufacturing Units:
- CP I: Puducherry
- CP X: Vishakhapatnam

Research & Development:
- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: Formulation R&D, Perungudi, Chennai

Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

Caplin Point Far East Ltd

Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

Caplin One Labs Ltd (COL)

Manufacturing Unit:
- SIDCO, Kakkalur (Near Chennai)

Caplin Steriles Ltd (India)

Manufacturing Units:
- CP IV: Gummidipoondi

Research & Development:
- Perungudi, Chennai
- Gummidipoondi


- Sunsole Solar Private Ltd (Associate of CSL)

Caplin Steriles USA Inc (US)

Distribution:
- Front-end trading arm for the sale of products in the USA

Manufacturing and R&D Platform

Caplin Point Laboratories Limited





Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam



CP I
Puducherry



CP IV
Gummidipoondi



Corporate Office and other R&D units:
Chennai



CP III
Chengalpattu



CP VI
Hyderabad



CP VII
Chennai

Note. CP III, CP VI and CP VII are for Research and Development

Strategic Investments

Caplin Point Laboratories Limited

Project Summary					
Facility	**Location**	**Product**	**Target Market**	**Status**	**Timeline**
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity completed	CY27
OSD Facility	Puducherry	OSD and Dermatology	New Market such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmic	Regulated Markets	Civil & Structural activity ongoing at full swing	Q2 FY28

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the investments are expected to be completed over the next 2 years, and the respective projects are expected to be fully commercialised within 1 year from the completion of the investments. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.

Caplin Point's Investment Case

Caplin Point Laboratories Limited

Core Business to show consistent growth	Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows
US Business to Boost the Growth	Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth
Backed by Enhanced Value Chain	Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings
Strong Balance Sheet	Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision
Expansion into Other Geographies and Widening of the Portfolio	Caplin plans to enter more regulated markets such as Canada, Australia, MENA as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

Experienced and Visionary Board of Directors (1/2)

Caplin Point Laboratories Limited



Mr. C.C. Paarthipan

Chairman

40+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid



Dr. Sridhar Ganesan

Managing Director

35+ Years of experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS



Mr. Ashok Partheeban

Vice Chairman

23+ Years of experience in Pharmaceutical Industry

Oversees the entire LATAM operations since 2002 as well as other emerging markets

Spearheaded market expansion and growth initiatives in the LATAM region

Holds an Associate's Degree in OPM from Harvard Business School and a Bachelor's in Marketing from Middlesex University



Mr. Vivek Partheeban

Vice Chairman

20+ Years of experience in the pharmaceutical industry

Was COO at Caplin Point Laboratories Ltd, Oversees the entire U.S/regulated market. operations

Educated at Harvard Business School and Monash University

Honorary Consul for the Republic of Guatemala in Chennai since 2018



Mr. D. Muralidharan

Whole Time Director and CFO

Is a seasoned finance professional with a bachelor's degree in commerce, Associate Membership of the Institute of Company Secretaries of India, and Cost and Management Accountant from the Institute of Cost Accountants of India.

Has over four decades of rich and diverse experience in finance, corporate governance, management and administration, contributing significantly to the Company's financial management and governance practices

Experienced and Visionary Board of Directors (2/2)

Caplin Point Laboratories Limited



Dr. KC John

Independent Director

35+ Years of experience in sustainable development

Held leadership roles in start-ups, tech ventures, and acquisitions

Expert for Tamil Nadu Industrial Development Corporation

Doctorate in Management from Indian Institute of Management, Ahmedabad



Dr. R Nagendran

Independent Director

Ph.D in Ecology and Ethology and M.SC in Zoology

Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore.



Mr S Deenadayalan

Independent Director

Post Graduate degree in Social Work from Madras School of Social Work and Under Graduate degree in Sociology from Annamalai University

Has extensively worked and mentors individuals enabling them to become successful professionals and more than 30,000 municipal school students have been benefitted by his idealistic model.



Mr. R. Vijayaraghavan

Independent Director

35+ years of experience as a taxation expert with consulting and litigation practice across India

Advises major corporate groups in South India on Direct Taxes, Tax Planning, Tax Litigations

Specializes in advising on taxation of non-residents, joint ventures & collaborations, double taxation avoidance agreements & transfer pricing issues.



Mrs. Susan Mathew

Independent Director

Post Graduate degree from Union Christian College and Graduate of Women's Christian College, Chennai

Served 36 years in senior IAS positions, including as Principal Secretary to the Governor

She contributed to key policies like private power projects and the Comprehensive Transport Policy in Tamil Nadu

Q2 FY27 Consolidated Income Statement

Caplin Point Laboratories Limited

In Rs. Crores

Particulars	Q2 FY27	Q2 FY26	YoY (%)	Q1 FY27	QoQ (%)	H1 FY27	H1 FY26	YoY (%)
Revenue from Operations	629.84	534.04	17.9%	610.36	3.2%	1,240.20	1,044.26	18.8%
Other Income	33.29	30.37	9.6%	33.55	(0.8)%	66.84	53.51	24.9%
Total Revenue	**663.13**	**564.41**	**17.5%**	**643.91**	**3.0%**	**1,307.04**	**1,097.77**	**19.1%**
Cost of Goods sold	28.67	210.30	13.5%	245.20	(2.7)%	483.87	405.54	19.3%
Gross Profit (Excluding Other Income)	**391.17**	**323.74**	**20.8%**	**365.16**	**7.1%**	**756.33**	**638.72**	**18.4%**
Gross Profit Margin (on Rev from Operations)	***62.1%***	***60.6%***		***59.8%***		***61.0%***	***61.2%***	
Employee Benefit Expenses	57.59	48.03	19.9%	57.03	1.0%	114.62	92.08	24.5%
Research and Development expenses	23.74	21.45	10.7%	21.30	11.5%	45.04	39.41	14.3%
Other operating expenses	86.62	65.09	33.1%	73.35	18.1%	159.97	140.30	14.0%
Total expenditure	**167.95**	**134.57**	**24.8%**	**151.68**	**10.8%**	**319.63**	**271.79**	**17.6%**
EBITDA	**256.51**	**219.54**	**16.8%**	**247.03**	**3.8%**	**503.54**	**420.44**	**19.8%**
EBITDA Margin	***38.7%***	***38.9%***		***38.4%***		***38.5%***	***38.3%***	
Depreciation and Amortisation	23.49	18.40	27.6%	21.62	8.6%	45.11	34.69	30.0%
EBIT	**233.02**	**201.14**	**15.8%**	**225.41**	**3.4%**	**458.43**	**385.75**	**18.8%**
EBIT Margin	***35.1%***	***35.6%***		***35.0%***		***35.1%***	***35.1%***	
Finance Cost	*0.22*	*0.16*		*0.18*		0.40	0.34	
Share of Profit/(Loss) in associates	*0.03*	*0.02*		*(0.01)*		*0.02*	*0.05*	
Profit Before Tax	**232.83**	**201.00**	***15.8%***	**225.22**	***3.4%***	**458.05**	**385.46**	***18.8%***
PBT Margin	***35.1%***	***35.6%***		***35.0%***		***35.0%***	***35.1%***	
Tax	50.48	40.77	*23.8%*	46.13	*9.4%*	96.61	74.47	*29.7%*
Profit after Tax	**182.35**	**160.23**	***13.8%***	**179.09**	***1.8%***	**361.42**	**310.99**	***16.2%***
PAT Margin	***27.5%***	***28.4%***		***27.8%***		***27.7%***	***28.3%***	

ESG and CSR

Caplin Point Laboratories Limited

ESG Commitments



Community Development

✓ Caplin Group's state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai



Recycled Waste

✓ 53.8 MT waste recycled in FY25/26



Environmental &Social

✓ Low carbon footprint

✓ Women empowerment

✓ Investments in rural healthcare

CSR

INR 4.16 Crores

Amount spent on CSR in FY26

INR 3.47 Crores

Amount spent on CSR in H1 FY27

Disclaimer

Caplin Point Laboratories Limited

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.

Caplin Point
Laboratories Limited

Mr G Venkatram

investors@caplinpoint.net

Churchgate
Investor Relations

Soham Arora / Simran Malhotra

+91 73032 11037

caplinpoint@churchgatepartners.com

BSE 524742 NSE CAPLIPOINT

CIN: L24231TN1990PLC019053

ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

"Caplin Point" and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.



Brahmayya&co.
Chartered Accountants

Independent Auditor's Review Report on Unaudited Standalone Quarterly and Year-to-Date Financial Results of Caplin Point Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Caplin Point Laboratories Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Caplin Point Laboratories Limited** (**"the Company"**), for the quarter ended 30th September 2026 and for the period from 1st April 2026 to 30th September 2026 (**"the Statement"**), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

2. The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No. 000511S

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575ROMSRS3749

Place: Chennai
Date: 12th November 2026

48, Masilamani Road, Balaji Nagar,
Royapettah, Chennai - 600 014. India.

T : +91- 044 - 2813 1128 / 38 / 48 / 58
E : mail@brahmayya.com | www.brahmayya.com

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and Year-to-Date Financial Results of Caplin Point Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Caplin Point Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Caplin Point Laboratories Limited** ("**the Holding Company**"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as "**the Group**") and its share in the net loss after tax and total comprehensive loss of associate for the quarter ended 30th September 2026 and for the period from 1st April 2026 to 30th September 2026 ("**the Statement**"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

2. The Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Caplin Point Laboratories Limited	Holding Company

Subsidiary Companies

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary
Caplin One Labs Limited, India *(Formerly known as Caplin Onco Limited)*	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary

Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary
Neoethicals Chile SpA, Chile	Step Down Subsidiary
Triwin Pharma S.A DE C.V Mexico, Mexico	Step Down Subsidiary

Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

Associate Company of Caplin Steriles Limited

Name of the Entity	Relationship
Sunsole Solar Private Limited, India	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of five subsidiaries and eight step-down subsidiaries included in the Statement, whose interim financial results reflect total assets of INR 4,188.77 crores as at 30th September 2026 and total revenue of INR 721.65 crores and INR 1,356.98 crores, total net profit after tax of INR 101.12 crores and INR 208.55 crores, total comprehensive income of INR 108.48 crores and INR 232.45 crores, for the quarter ended 30th September 2026 and for the period from 1st April 2026 to 30th September 2026, respectively and net cash outflow of INR 57.94 crores for the period from 1st April 2026 to 30th September 2026 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and step-down subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

7. The Statement includes the interim financial results of one step-down subsidiary, which have not been reviewed by their auditors, whose interim financial results reflect total assets of INR 25.20 crores as at 30th September 2026, and total revenue of INR 0.09 crores and INR 0.14 crores, total net loss of INR 0.19 Crores and INR INR 1.41 crores and total comprehensive loss of INR 1.31 crores and INR 1.67 crores for the quarter ended 30th September 2026 and for the period from 1st April 2026 to 30th September 2026, respectively and net cash outflow of INR 3.05 crores for the period from 1st April 2026 to 30th September 2026 as considered in the Statement. The Statement also includes the Group's share of net profit after tax and total comprehensive income of INR 0.02 crores and INR 0.01 crores, for the quarter ended 30th September 2026 and for the period from 1st April 2026 to 30th September 2026, respectively, as considered in the Statement in respect of an associate, based on their interim financial results which have not been reviewed by their auditor. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No. 000511S

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575WPGAJG2101

Place: Chennai
Date: 12th November 2026